Gosuranemab clinical trials
Also written BIIB092 and BMS-986168.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How each study uses gosuranemab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Studies
Open first, then newest update. How each study uses gosuranemab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Phase 2 Study of BIIB092 in Participants With Early Alzheimer's DiseaseTerminatedPhase 2BiogenNCT03352557Written as BIIB092
- Study of BIIB092 in Participants With Progressive Supranuclear PalsyTerminatedPhase 2BiogenNCT03068468Written as BIIB092
- Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003TerminatedPhase 1BiogenNCT02658916Written as BIIB092
- BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TESTerminatedPhase 1University of California, San FranciscoNCT03658135Written as BIIB092
- Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear PalsyCompletedPhase 1BiogenNCT02460094Written as BIIB092
- A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy SubjectsCompletedPhase 1BiogenNCT02294851Written as BMS-986168
Codes
What other systems call gosuranemab · ClinicalTrials.gg INT001328
- MeSH (NLM) C000707052gosuranemabOne source NLM
- UNII (FDA) 09FZ7Q0PQZGOSURANEMABConfirmed FDA, NLM
- NCI Thesaurus C175078GosuranemabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000707052 | gosuranemab | One source NLM |
| UNII (FDA) | 09FZ7Q0PQZ | GOSURANEMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C175078 | Gosuranemab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.